Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|November 8, 2022

BP Elements

  • BioPharm International's BP Elements, November 2022
  • Volume 1
  • Issue 11

Shimadzu and UMG Göttingen Enter Analytics Collaboration

The collaboration will see Shimadzu and UMG develop new clinical laboratory methods using LC-MS for TDM analysis.

Shimadzu, a laboratory instruments supplier, and University Medical Center Göttingen (UMG), announced a collaboration to develop new clinical laboratory methods. The focus of their research will be on using liquid chromatography-mass-spectrometry (LC-MS) for therapeutic drug monitoring (TDM) analysis. The collaboration is being performed under Shimadzu’s European Innovation Center program, which is designed to enable collaborations where outside experts can work with Shimadzu technologies.

According to a Oct. 27, 2022 press release, TDM tests, which measure the concentration of drugs currently in blood, have usually been done through an immunoassay, but LC-MS methods have recently grown in popularity due to advantages in strength and accuracy. However, complexity of sample preparation has prevented widespread adoption.

The collaboration will focus on developing Shimadzu's CLAM-2030, a fully automated sample preparation module for LC-MS. The device functions by placing blood collection tubes in position, wherein the module automatically performs sample pretreatment steps up to LC/MS/MS analysis. The collaboration aims to develop new methods for multiple target groups of drugs, as well as means of switching between these new methods easily and quickly.

Source: Shimadzu


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.